{
    "hands_on_practices": [
        {
            "introduction": "The ultimate goal of pharmacogenetics is to tailor medical treatment to an individual's genetic makeup. This practice puts you in the role of a clinician applying this principle to dose adjustment. Using a simplified but powerful first-order kinetic model, you will calculate an individualized dose of succinylcholine for a patient with reduced BChE activity, ensuring both efficacy and safety. This exercise highlights how fundamental pharmacokinetic relationships can be used to translate genetic information directly into a life-saving clinical decision .",
            "id": "5017468",
            "problem": "A clinician is planning to use succinylcholine in a patient known to carry a variant in the butyrylcholinesterase (BChE) gene that reduces enzyme activity. Butyrylcholinesterase (BChE) is the plasma esterase responsible for rapid hydrolysis of succinylcholine; under standard clinical conditions and doses, succinylcholine elimination is well-approximated by first-order kinetics in a one-compartment model, and the enzyme is not saturated. In this model, the plasma concentration $C(t)$ after an intravenous bolus dose $D$ satisfies $C(t) = C_{0} \\exp(-k t)$, with $C_{0} = D/V_{d}$ and $k = \\mathrm{CL}/V_{d}$, where $V_{d}$ is the volume of distribution and $\\mathrm{CL}$ is the clearance. Paralysis ends when $C(t)$ falls to a pharmacodynamic threshold $C_{\\text{paralysis}}$ that is patient-independent.\n\nAssume the following foundational relationships:\n- Succinylcholine obeys first-order elimination with $k = \\mathrm{CL}/V_{d}$.\n- The measured BChE activity fraction $f$ scales succinylcholine clearance linearly: $\\mathrm{CL}_{\\text{patient}} = f \\,\\mathrm{CL}_{\\text{normal}}$.\n- The threshold concentration $C_{\\text{paralysis}}$ is identical across patients and does not depend on $f$.\n\nA standard patient with normal BChE activity ($f = 1$) receives a standard dose $D_{\\text{std}} = 1.0$ mg/kg and experiences the end of paralysis at time $T$ minutes after injection. The patient in question has measured BChE activity fraction $f$ and should be dosed so that the end of paralysis occurs at time $T$ minutes as well, thereby ensuring the paralysis duration is at most $T$.\n\nUse the parameters below, which are scientifically plausible for an adult:\n- Patient body mass $80$ kg.\n- Volume of distribution $V_{d} = 0.25$ L/kg.\n- Normal clearance $\\mathrm{CL}_{\\text{normal}} = 7.0$ L/min.\n- Target time $T = 8.0$ minutes.\n- Measured BChE activity fraction $f = 0.25$.\n- Standard dose $D_{\\text{std}} = 1.0$ mg/kg.\n\nCompute the individualized succinylcholine dose $D_{\\text{new}}$ for this patient, expressed in mg, that targets an end-of-paralysis time of $T$ minutes. Round your answer to four significant figures and express the dose in mg.",
            "solution": "The duration of paralysis is determined by the time it takes for the plasma concentration of succinylcholine, $C(t)$, to decrease to a specific pharmacodynamic threshold, $C_{\\text{paralysis}}$. The concentration at time $t$ after an intravenous bolus dose $D$ is given by the one-compartment model equation:\n$$C(t) = C_{0} \\exp(-k t)$$\nwhere $C_{0} = D/V_{d}$ is the initial concentration, $V_{d}$ is the total volume of distribution, and $k = \\mathrm{CL}/V_{d}$ is the first-order elimination rate constant, with $\\mathrm{CL}$ being the drug clearance.\n\nSubstituting the expressions for $C_0$ and $k$ into the concentration equation, we get:\n$$C(t) = \\frac{D}{V_{d}} \\exp\\left(-\\frac{\\mathrm{CL}}{V_{d}}t\\right)$$\n\nParalysis ends at time $t=T$ when $C(T) = C_{\\text{paralysis}}$. Thus, for any patient:\n$$C_{\\text{paralysis}} = \\frac{D}{V_{d}} \\exp\\left(-\\frac{\\mathrm{CL}}{V_{d}}T\\right)$$\n\nWe analyze two scenarios: the standard patient and the patient with the BChE variant.\n\n**Scenario 1: Standard Patient**\nThis patient has normal enzyme activity, so their activity fraction is $f_1 = 1$.\n- Dose: $D_1 = D_{\\text{std}} \\times M = (1.0 \\, \\text{mg/kg}) \\times (80 \\, \\text{kg}) = 80 \\, \\text{mg}$.\n- Total volume of distribution: $V_{d, \\text{total}} = V_{d, \\text{specific}} \\times M = (0.25 \\, \\text{L/kg}) \\times (80 \\, \\text{kg}) = 20 \\, \\text{L}$.\n- Clearance: $\\mathrm{CL}_1 = \\mathrm{CL}_{\\text{normal}} = 7.0 \\, \\text{L/min}$.\n- End of paralysis time: $T = 8.0 \\, \\text{minutes}$.\n\nFor the standard patient, the threshold concentration is:\n$$C_{\\text{paralysis}} = \\frac{D_1}{V_{d, \\text{total}}} \\exp\\left(-\\frac{\\mathrm{CL}_1}{V_{d, \\text{total}}}T\\right)$$\n\n**Scenario 2: Patient with BChE Variant**\nThis patient has reduced enzyme activity with a fraction $f_2 = 0.25$.\n- Dose: $D_2 = D_{\\text{new}}$ (the quantity to be determined).\n- Total volume of distribution: Assumed to be the same as the standard patient, $V_{d, \\text{total}} = 20 \\, \\text{L}$.\n- Clearance: $\\mathrm{CL}_2 = f_2 \\cdot \\mathrm{CL}_{\\text{normal}} = 0.25 \\cdot \\mathrm{CL}_{\\text{normal}}$.\n- End of paralysis time: The target is the same, $T = 8.0 \\, \\text{minutes}$.\n\nFor this patient, the equation is:\n$$C_{\\text{paralysis}} = \\frac{D_2}{V_{d, \\text{total}}} \\exp\\left(-\\frac{\\mathrm{CL}_2}{V_{d, \\text{total}}}T\\right)$$\n\n**Solving for the new dose, $D_{\\text{new}}$**\nThe problem states that $C_{\\text{paralysis}}$ is patient-independent and the target time $T$ is the same for both scenarios. Therefore, we can equate the expressions for $C_{\\text{paralysis}}$ from both scenarios:\n$$\\frac{D_1}{V_{d, \\text{total}}} \\exp\\left(-\\frac{\\mathrm{CL}_1}{V_{d, \\text{total}}}T\\right) = \\frac{D_2}{V_{d, \\text{total}}} \\exp\\left(-\\frac{\\mathrm{CL}_2}{V_{d, \\text{total}}}T\\right)$$\n\nThe term $V_{d, \\text{total}}$ in the denominator of the pre-exponential factor cancels out on both sides:\n$$D_1 \\exp\\left(-\\frac{\\mathrm{CL}_1 T}{V_{d, \\text{total}}}\\right) = D_2 \\exp\\left(-\\frac{\\mathrm{CL}_2 T}{V_{d, \\text{total}}}\\right)$$\n\nWe solve for $D_2$, which is our desired dose $D_{\\text{new}}$:\n$$D_2 = D_1 \\frac{\\exp\\left(-\\frac{\\mathrm{CL}_1 T}{V_{d, \\text{total}}}\\right)}{\\exp\\left(-\\frac{\\mathrm{CL}_2 T}{V_{d, \\text{total}}}\\right)}$$\nUsing the property of exponents $\\exp(a)/\\exp(b) = \\exp(a-b)$:\n$$D_2 = D_1 \\exp\\left(-\\frac{\\mathrm{CL}_1 T}{V_{d, \\text{total}}} + \\frac{\\mathrm{CL}_2 T}{V_{d, \\text{total}}}\\right)$$\n$$D_2 = D_1 \\exp\\left(\\frac{T}{V_{d, \\text{total}}}(\\mathrm{CL}_2 - \\mathrm{CL}_1)\\right)$$\n\nNow, substitute $\\mathrm{CL}_1 = \\mathrm{CL}_{\\text{normal}}$ and $\\mathrm{CL}_2 = f_2 \\cdot \\mathrm{CL}_{\\text{normal}}$:\n$$D_2 = D_1 \\exp\\left(\\frac{T}{V_{d, \\text{total}}}(f_2 \\cdot \\mathrm{CL}_{\\text{normal}} - \\mathrm{CL}_{\\text{normal}})\\right)$$\n$$D_{\\text{new}} = D_1 \\exp\\left(\\frac{T \\cdot \\mathrm{CL}_{\\text{normal}}}{V_{d, \\text{total}}}(f_2 - 1)\\right)$$\n\nNow we substitute the numerical values into this expression:\n- $D_1 = 80 \\, \\text{mg}$\n- $T = 8.0 \\, \\text{min}$\n- $\\mathrm{CL}_{\\text{normal}} = 7.0 \\, \\text{L/min}$\n- $V_{d, \\text{total}} = 20 \\, \\text{L}$\n- $f_2 = 0.25$\n\nThe argument of the exponential function is:\n$$\\frac{(8.0 \\, \\text{min}) \\cdot (7.0 \\, \\text{L/min})}{20 \\, \\text{L}}(0.25 - 1) = \\frac{56.0}{20} (-0.75) = 2.8 \\cdot (-0.75) = -2.1$$\nNote that the units in the exponent cancel out, as required.\n\nNow, we calculate $D_{\\text{new}}$:\n$$D_{\\text{new}} = 80 \\, \\text{mg} \\cdot \\exp(-2.1)$$\n$$D_{\\text{new}} \\approx 80 \\cdot 0.122456428... \\, \\text{mg}$$\n$$D_{\\text{new}} \\approx 9.7965142... \\, \\text{mg}$$\n\nThe problem requires rounding the answer to four significant figures.\n$$D_{\\text{new}} \\approx 9.797 \\, \\text{mg}$$\nThis result is logical: a patient with significantly reduced enzyme activity (lower clearance) requires a much smaller dose to achieve the same duration of effect as a person with normal metabolism.",
            "answer": "$$\\boxed{9.797}$$"
        },
        {
            "introduction": "To truly understand why a genetic deficiency prolongs a drug's effect, we must move beyond simplified models and examine the underlying enzyme kinetics. This problem challenges you to derive the relationship between drug concentration and time using the more accurate Michaelis-Menten model for enzyme-catalyzed reactions. By solving the governing differential equation, you will derive a precise, analytical expression that quantifies exactly how the duration of succinylcholine's effect is inversely proportional to BChE enzyme activity, providing a rigorous foundation for the clinical observations .",
            "id": "5017466",
            "problem": "A single bolus of succinylcholine (SCh) is administered intravenously to an adult. Succinylcholine is eliminated predominantly by hydrolysis in plasma by Butyrylcholinesterase (BChE). Consider a one-compartment, well-mixed plasma model in which SCh concentration, denoted by $C(t)$, is reduced solely by BChE-mediated hydrolysis following single-substrate enzyme kinetics. Assume the following foundational facts: (i) the maximal catalytic capacity is proportional to the total enzyme concentration, so that $V_{\\max} = k_{\\mathrm{cat}} [E]_{\\mathrm{T}}$, and (ii) the affinity parameter $K_{m}$ does not depend on the enzyme concentration. Let the initial plasma concentration immediately after the bolus be $C_{0}$ and neuromuscular function be considered clinically recovered once the plasma concentration falls below a threshold $C_{\\mathrm{thr}}$.\n\nA genetic variant causing BChE deficiency reduces the total enzyme concentration to a fraction $\\alpha$ of normal, with $0 < \\alpha < 1$, while leaving $K_{m}$ unchanged. You may model the time course of $C(t)$ solely from mass conservation in the single compartment and the above enzyme-kinetic assumptions.\n\nTasks:\n1. Starting from first principles of mass balance in a single compartment and single-substrate enzyme kinetics, derive an exact closed-form expression for the time $T\\!\\left(V_{\\max}, K_{m}, C_{0}, C_{\\mathrm{thr}}\\right)$ required for the SCh concentration to decline from $C_{0}$ to $C_{\\mathrm{thr}}$ after the bolus.\n2. Using the result from part 1 and the relationship $V_{\\max} \\propto [E]_{\\mathrm{T}}$, obtain a closed-form expression for the ratio $R(\\alpha) = \\dfrac{T_{\\text{deficient}}}{T_{\\text{normal}}}$.\n3. Evaluate $R(\\alpha)$ numerically for $\\alpha = 0.250$. Round your answer to three significant figures. Express the final result as a pure number without units.\n\nYou may assume the following clinically plausible values for context (they are not required to compute $R(\\alpha)$): a bolus dose of $1.0 \\ \\mathrm{mg}\\,\\mathrm{kg}^{-1}$, an apparent volume of distribution of $0.20 \\ \\mathrm{L}\\,\\mathrm{kg}^{-1}$, and a clinical recovery threshold $C_{\\mathrm{thr}} = 0.50 \\ \\mathrm{mg}\\,\\mathrm{L}^{-1}$.",
            "solution": "### Solution\n\n**Part 1: Derivation of the time $T$**\n\nThe rate of change of the SCh concentration, $C(t)$, in a single compartment where elimination is governed by Michaelis-Menten kinetics is described by the following first-order ordinary differential equation:\n$$\n\\frac{dC}{dt} = - \\frac{V_{\\max} C}{K_{m} + C}\n$$\nHere, $V_{\\max}$ is the maximum rate of elimination and $K_{m}$ is the Michaelis constant, which is the substrate concentration at which the reaction rate is half of $V_{\\max}$. The negative sign indicates that the concentration is decreasing over time.\n\nTo find the time $T$ required for the concentration to decrease from an initial value $C_{0}$ to a threshold value $C_{\\mathrm{thr}}$, we must solve this differential equation. We can separate the variables $C$ and $t$:\n$$\ndt = - \\frac{K_{m} + C}{V_{\\max} C} dC\n$$\nWe integrate both sides of the equation. The time $t$ goes from $0$ to $T$, while the concentration $C$ goes from $C_0$ to $C_{\\mathrm{thr}}$:\n$$\n\\int_{0}^{T} dt = \\int_{C_{0}}^{C_{\\mathrm{thr}}} - \\frac{K_{m} + C}{V_{\\max} C} dC\n$$\nTo simplify the integration, we can reverse the limits of integration on the right side, which removes the negative sign:\n$$\nT = \\int_{C_{\\mathrm{thr}}}^{C_{0}} \\frac{K_{m} + C}{V_{\\max} C} dC\n$$\nWe can separate the integrand into two terms:\n$$\nT = \\frac{1}{V_{\\max}} \\int_{C_{\\mathrm{thr}}}^{C_{0}} \\left( \\frac{K_{m}}{C} + 1 \\right) dC\n$$\nNow, we perform the integration with respect to $C$:\n$$\nT = \\frac{1}{V_{\\max}} \\left[ K_{m} \\ln|C| + C \\right]_{C_{\\mathrm{thr}}}^{C_{0}}\n$$\nSince concentration is always non-negative, the absolute value is not necessary. Evaluating the definite integral gives:\n$$\nT = \\frac{1}{V_{\\max}} \\left( (K_{m} \\ln(C_{0}) + C_{0}) - (K_{m} \\ln(C_{\\mathrm{thr}}) + C_{\\mathrm{thr}}) \\right)\n$$\nCombining the terms, we arrive at the final closed-form expression for $T$:\n$$\nT = T(V_{\\max}, K_{m}, C_{0}, C_{\\mathrm{thr}}) = \\frac{1}{V_{\\max}} \\left( K_{m} \\ln\\left(\\frac{C_{0}}{C_{\\mathrm{thr}}}\\right) + C_{0} - C_{\\mathrm{thr}} \\right)\n$$\n\n**Part 2: Derivation of the ratio $R(\\alpha)$**\n\nThe problem states that a BChE-deficient individual has a total enzyme concentration that is a fraction $\\alpha$ of the normal concentration. The maximal velocity $V_{\\max}$ is directly proportional to the total enzyme concentration $[E]_{\\mathrm{T}}$, stated as $V_{\\max} = k_{\\mathrm{cat}} [E]_{\\mathrm{T}}$.\n\nLet $V_{\\max, \\text{normal}}$ be the maximal velocity in an individual with normal BChE levels, corresponding to an enzyme concentration $[E]_{\\mathrm{T, normal}}$.\n$$V_{\\max, \\text{normal}} = k_{\\mathrm{cat}} [E]_{\\mathrm{T, normal}}$$\nFor a deficient individual, the enzyme concentration is $[E]_{\\mathrm{T, deficient}} = \\alpha [E]_{\\mathrm{T, normal}}$. The corresponding maximal velocity is:\n$$V_{\\max, \\text{deficient}} = k_{\\mathrm{cat}} [E]_{\\mathrm{T, deficient}} = k_{\\mathrm{cat}} (\\alpha [E]_{\\mathrm{T, normal}}) = \\alpha (k_{\\mathrm{cat}} [E]_{\\mathrm{T, normal}}) = \\alpha V_{\\max, \\text{normal}}$$\nThe problem specifies that $K_{m}$ is unchanged. The initial concentration $C_{0}$ (determined by dose and volume of distribution) and the threshold concentration $C_{\\mathrm{thr}}$ (a clinical definition) are also independent of the enzyme variant.\n\nUsing the expression for $T$ derived in Part 1, we can write the time for a normal and a deficient individual:\n$$T_{\\text{normal}} = \\frac{1}{V_{\\max, \\text{normal}}} \\left( K_{m} \\ln\\left(\\frac{C_{0}}{C_{\\mathrm{thr}}}\\right) + C_{0} - C_{\\mathrm{thr}} \\right)$$\n$$T_{\\text{deficient}} = \\frac{1}{V_{\\max, \\text{deficient}}} \\left( K_{m} \\ln\\left(\\frac{C_{0}}{C_{\\mathrm{thr}}}\\right) + C_{0} - C_{\\mathrm{thr}} \\right)$$\nsubstituting $V_{\\max, \\text{deficient}} = \\alpha V_{\\max, \\text{normal}}$ into the expression for $T_{\\text{deficient}}$:\n$$T_{\\text{deficient}} = \\frac{1}{\\alpha V_{\\max, \\text{normal}}} \\left( K_{m} \\ln\\left(\\frac{C_{0}}{C_{\\mathrm{thr}}}\\right) + C_{0} - C_{\\mathrm{thr}} \\right)$$\nNow we compute the ratio $R(\\alpha) = \\dfrac{T_{\\text{deficient}}}{T_{\\text{normal}}}$:\n$$\nR(\\alpha) = \\frac{\\frac{1}{\\alpha V_{\\max, \\text{normal}}} \\left( K_{m} \\ln\\left(\\frac{C_{0}}{C_{\\mathrm{thr}}}\\right) + C_{0} - C_{\\mathrm{thr}} \\right)}{\\frac{1}{V_{\\max, \\text{normal}}} \\left( K_{m} \\ln\\left(\\frac{C_{0}}{C_{\\mathrm{thr}}}\\right) + C_{0} - C_{\\mathrm{thr}} \\right)}\n$$\nThe term in the large parentheses is a non-zero constant that cancels out, as does $V_{\\max, \\text{normal}}$. This leaves a remarkably simple result:\n$$\nR(\\alpha) = \\frac{1/\\alpha}{1} = \\frac{1}{\\alpha}\n$$\nThis expression shows that the duration of action of succinylcholine is inversely proportional to the fractional activity of the BChE enzyme, a direct consequence of the structure of the Michaelis-Menten rate law.\n\n**Part 3: Numerical evaluation of $R(\\alpha)$**\n\nThe problem asks for the numerical value of $R(\\alpha)$ when the enzyme concentration is reduced to a fraction $\\alpha = 0.250$ of normal.\nUsing the expression from Part 2:\n$$\nR(0.250) = \\frac{1}{0.250} = 4\n$$\nThe input value $\\alpha = 0.250$ is given with three significant figures. The numerator $1$ is an exact number. Therefore, the result should be reported to three significant figures.\n$$\nR(0.250) = 4.00\n$$\nThis result implies that an individual with only $25\\%$ of the normal BChE activity will experience the effects of succinylcholine for a duration that is $4$ times longer than a person with normal enzyme activity, under the assumptions of this model.",
            "answer": "$$\\boxed{4.00}$$"
        },
        {
            "introduction": "Identifying patients at risk for adverse reactions to succinylcholine relies on laboratory testing that can distinguish between different BChE variants. This practice explores the biochemical principle behind the \"dibucaine number,\" a classic diagnostic test that measures the inhibition of BChE activity. By applying the model of competitive inhibition, you will calculate the expected percent inhibition for both the usual and atypical enzyme variants, gaining insight into how kinetic parameters like $K_m$ and $K_i$ determine the diagnostic outcome .",
            "id": "5017489",
            "problem": "A patient’s risk of prolonged apnea after succinylcholine administration can be inferred by measuring how effectively Butyrylcholinesterase (BChE) is inhibited by dibucaine at a defined experimental inhibitor concentration. Consider two human BChE genetic variants: the usual variant (U) and the atypical variant (A). Succinylcholine is hydrolyzed by BChE according to Michaelis–Menten kinetics, and dibucaine binds the free enzyme competitively with respect to succinylcholine. Assume steady-state enzyme kinetics with a single substrate and a single competitive inhibitor, and neglect product inhibition.\n\nYou are given the following experimentally determined parameters for the two variants under standard assay conditions:\n- Usual variant U: Michaelis constant for succinylcholine $K_{m}^{U} = 40\\,\\mu\\mathrm{M}$; inhibitory constant for dibucaine $K_{i}^{U} = 1\\,\\mu\\mathrm{M}$.\n- Atypical variant A: Michaelis constant for succinylcholine $K_{m}^{A} = 100\\,\\mu\\mathrm{M}$; inhibitory constant for dibucaine $K_{i}^{A} = 25\\,\\mu\\mathrm{M}$.\n\nIn the assay, succinylcholine concentration is fixed at $[S] = 50\\,\\mu\\mathrm{M}$ and dibucaine concentration is fixed at $[I] = 10\\,\\mu\\mathrm{M}$.\n\nStarting from the definition of the Michaelis–Menten initial velocity $v$ for a single-substrate enzyme and the standard competitive inhibition model (in which the apparent Michaelis constant increases while the maximal velocity remains unchanged), derive the fractional activity in the presence of inhibitor relative to the uninhibited rate and define the percent inhibition as the fraction of activity lost. Then, using those definitions, compute the ratio of the percent inhibition for the usual variant to that for the atypical variant, that is,\n$$\\frac{\\pi_{U}}{\\pi_{A}},$$\nwhere $\\pi_{U}$ and $\\pi_{A}$ denote the percent inhibition (expressed as a decimal fraction, not a percentage) for U and A, respectively, under the specified conditions. Express your final answer as a dimensionless decimal number and round your result to four significant figures.",
            "solution": "The initial velocity, $v$, of an enzyme-catalyzed reaction following Michaelis–Menten kinetics is given by the equation:\n$$v = \\frac{V_{max} [S]}{K_m + [S]}$$\nwhere $V_{max}$ is the maximal velocity, $[S]$ is the substrate concentration, and $K_m$ is the Michaelis constant.\n\nIn the case of competitive inhibition, the inhibitor, $[I]$, binds to the free enzyme, which increases the apparent Michaelis constant, $K_{m,app}$. The maximal velocity, $V_{max}$, is unaffected. The relationship is:\n$$K_{m,app} = K_m \\left( 1 + \\frac{[I]}{K_i} \\right)$$\nwhere $K_i$ is the dissociation constant for the enzyme-inhibitor complex.\n\nThe velocity in the presence of a competitive inhibitor, $v_i$, is therefore:\n$$v_i = \\frac{V_{max} [S]}{K_{m,app} + [S]} = \\frac{V_{max} [S]}{K_m \\left( 1 + \\frac{[I]}{K_i} \\right) + [S]}$$\nThe fractional activity is the ratio of the inhibited velocity to the uninhibited velocity, $v_i/v_0$.\n$$ \\frac{v_i}{v_0} = \\frac{\\frac{V_{max} [S]}{K_m \\left( 1 + \\frac{[I]}{K_i} \\right) + [S]}}{\\frac{V_{max} [S]}{K_m + [S]}} $$\nThe term $V_{max}[S]$ cancels, yielding:\n$$ \\frac{v_i}{v_0} = \\frac{K_m + [S]}{K_m \\left( 1 + \\frac{[I]}{K_i} \\right) + [S]} = \\frac{K_m + [S]}{K_m + K_m\\frac{[I]}{K_i} + [S]} $$\nThe percent inhibition, $\\pi$, is defined as the fraction of activity lost. This is equivalent to $1$ minus the fractional activity.\n$$ \\pi = 1 - \\frac{v_i}{v_0} = 1 - \\frac{K_m + [S]}{K_m + K_m\\frac{[I]}{K_i} + [S]} $$\nPlacing the terms over a common denominator:\n$$ \\pi = \\frac{\\left(K_m + K_m\\frac{[I]}{K_i} + [S]\\right) - \\left(K_m + [S]\\right)}{K_m + K_m\\frac{[I]}{K_i} + [S]} $$\nSimplifying the numerator gives the general expression for percent inhibition under competitive inhibition:\n$$ \\pi = \\frac{K_m\\frac{[I]}{K_i}}{K_m + [S] + K_m\\frac{[I]}{K_i}} $$\nWe now apply this formula to the two BChE variants using the provided assay conditions: $[S] = 50\\,\\mu\\mathrm{M}$ and $[I] = 10\\,\\mu\\mathrm{M}$.\n\nFor the usual variant (U), the parameters are $K_{m}^{U} = 40\\,\\mu\\mathrm{M}$ and $K_{i}^{U} = 1\\,\\mu\\mathrm{M}$. The percent inhibition, $\\pi_U$, is:\n$$ \\pi_U = \\frac{K_m^U \\frac{[I]}{K_i^U}}{K_m^U + [S] + K_m^U \\frac{[I]}{K_i^U}} = \\frac{40 \\left(\\frac{10}{1}\\right)}{40 + 50 + 40 \\left(\\frac{10}{1}\\right)} $$\n$$ \\pi_U = \\frac{40 \\times 10}{90 + 400} = \\frac{400}{490} = \\frac{40}{49} $$\n\nFor the atypical variant (A), the parameters are $K_{m}^{A} = 100\\,\\mu\\mathrm{M}$ and $K_{i}^{A} = 25\\,\\mu\\mathrm{M}$. The percent inhibition, $\\pi_A$, is:\n$$ \\pi_A = \\frac{K_m^A \\frac{[I]}{K_i^A}}{K_m^A + [S] + K_m^A \\frac{[I]}{K_i^A}} = \\frac{100 \\left(\\frac{10}{25}\\right)}{100 + 50 + 100 \\left(\\frac{10}{25}\\right)} $$\n$$ \\pi_A = \\frac{100 \\times 0.4}{150 + 100 \\times 0.4} = \\frac{40}{150 + 40} = \\frac{40}{190} = \\frac{4}{19} $$\n\nThe final task is to compute the ratio $\\frac{\\pi_U}{\\pi_A}$.\n$$ \\frac{\\pi_U}{\\pi_A} = \\frac{\\frac{40}{49}}{\\frac{4}{19}} = \\frac{40}{49} \\times \\frac{19}{4} $$\n$$ \\frac{\\pi_U}{\\pi_A} = \\frac{10 \\times 19}{49} = \\frac{190}{49} $$\nTo obtain the final numerical answer, we perform the division and round to four significant figures as requested.\n$$ \\frac{190}{49} \\approx 3.877551... $$\nRounding to four significant figures, the result is $3.878$.",
            "answer": "$$\\boxed{3.878}$$"
        }
    ]
}